HealthInvestor Asia Summit 2018
Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Analysis: Healthcare m&a to jump 80% in 2018

After a subdued 2017, healthcare mergers & acquisitions are expected to jump more than 80% this year in Asia Pacific to US$55.1 billion, according to global law firm Baker McKenzie.

Uncertainty in the wake of Brexit, the US presidential election and pending US tax reform cooled healthcare m&a activity in 2017. In 2018, however, Baker McKenzie is forecasting that current buoyant market conditions and clarity about the US’s new corporate tax rate will lead to a rebound in deal activity, causing global healthcare m&a to rise to US$418 billion, up 50% from US$277 billion last year.

In Asia Pacific, a major driver of m&a transactions continues to be big pharma buying manufacturing sites in lower cost jurisdictions like Vietnam and India. Pharma companies are also acquiring local companies for their distribution networks in emerging markets like China to gain access to the growing middle class that now has disposable income to spend on healthcare.

The total value of IPOs in the healthcare sector rose to US$15.7 billion in 2017, boosted by Chinese drug r&d company WuXi Biologics’ debut on the Hong Kong Stock Exchange in June, which raised more than US$580 million. In 2018, it forecasts healthcare IPOs to become even more active, rising to US$22.3 billion globally.

“We’re seeing a lot of biotechs get to the point where they need more capital for R&D and they’re debating whether to raise capital through an IPO or just sell the business now to take advantage of all-time high valuations,” said Tom Rice, a Baker McKenzie securities partner based in New York. “As a result, we’ve seen a resurgence over the last year or so of dual-track IPO sale processes seeking to maximise value.”

Healthtech companies are also likely to pursue IPOs to raise capital for R&D and to manufacture and open up new distribution channels for their products.

“The healthcare IPO market is beginning to gain surer footing as IPO valuations become more competitive with m&a,” said Ashok Lalwani, head of Baker McKenzie’s international capital markets practice in Asia Pacific. “As IPO valuations rise, we should start to see more of a trend towards companies using IPOs as an exit route as opposed to a trade sale.”

Following a peak in deal activity in 2018, the Baker McKenzie’s Global Transactions Forecast, developed in association with Oxford Economics, forecasts that healthcare m&a and IPO transactions will decline in 2019 in line with a larger, worldwide trend of cooling deal activity in developed markets. “As interest rates rise, global trade and investment growth slows, and equity prices correct, we forecast healthcare m&a to drop modestly to US$414 billion in 2019, and further to US$368 billion in 2020,” it said.

After reaching a five-year high of US$22.3 billion in 2018, IPOs in the healthcare sector are expected to drop slightly to US$21.4 billion in 2019 before declining further to US$17.7 billion in 2020.

Posted on: 11/01/2018 UTC+08:00


News

Medical glove manufacturer Careplus Group has extended plans for its M$7 million (US$1.7 million) private placement of shares to 31 July raising concerns that it is having difficulties getting the deal away.
First REIT, Singapore’s first healthcare real estate investment trust, has posted a distribution per unit (DPU) of S$0.0857 for the full year – the trust’s highest annual distribution since listing. This is a 1.2% increase on the DPU for the same period last year.
Healthcare services group Clearbridge Health has completed the acquisition of a 65% stake in Marzan Health Care, in Manila for Ps69.6 million (US$1.4 million).
Zhang Yi has stepped down as chief executive of Hang Seng-listed China Medical & HealthCare Group. He cited other business interests as the reason.
Details are emerging of the US$310 million loan that Top Glove is aiming for to help finance its M$1.4 billion (US$345 million) buyout of Adventa Capital-owned Aspion. The deal will make Top Glove the world’s largest surgical glove manufacturer, in addition to being the world’s largest rubber glove manufacturer.
Shares in Dublin-based and ASX listed IT healthcare company Oneview Healthcare rose 5% yesterday after hospital chain Mater Misericordiae signed an agreement to use its software.
Malaysian construction and engineering firm Zecon has delayed the sale of its 49% stake in Zecon Medicare to the State Financial Secretary of Sarawak for M$155 million (US$37.7 million).
KPJ Healthcare, the healthcare arm of the Johor Corporation, is in “advanced talks” to sell Jeta Gardens, its loss making aged care centre in Australia.



Analysis

Technologist, business leader, and philanthropist Bill Gates explains why global health needs the private sector.
Mitch Beaumont, Prashanth Prasad, Ulrica Sehlstedt and Mandeep Dhillon from international management consultants Arthur D. Little explain how medical technology companies can manage going digital.
Susann Roth, senior social development specialist, Asian Development Bank, argues why a health impact assessment is essential for hard infrastructure projects.
After a subdued 2017, healthcare mergers & acquisitions are expected to jump more than 80% this year in Asia Pacific to US$55.1 billion, according to global law firm Baker McKenzie.
After the Hong Kong High court found a doctor and a lab technician guilty of manslaughter, Michael Griffiths, regional director of healthcare at specialist insurance brokers Howden, looks at the extent of insurance or indemnity available to doctors in Asia accused of criminal acts.
Susann Roth, senior social development specialist, Asian Development Bank, looks at how Vietnam is building its digital health capacity.
The world’s first healthcare development impact bond aimed at reducing the number of maternal and newborn deaths in Rajasthan, India, launched last week.
The rise of 3D printing technology in medicine and healthcare is challenging existing regulatory frameworks as higher risk 3D printed medical devices are developed. Tracy Lu, senior associate for Allens in Sydney, explains that Australia is at the forefront of dealing with this regulatory reassessment.
my images

Podcasts

Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices